2025 年 12 月 11 日
ADC
What We Do
學術發表
2025 年 9 月 25 日
ADC
Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate
2025 年 5 月 23 日
Prodrug
Potentiation of AKR1C3- and P53-dependent AST-3424 activity via PUMA-mediated degradation of Rad51
2025 年 5 月 23 日
Prodrug
Preclinical evaluation of the AKR1C3-activated alkylator, OBI-3424, in hepatoblastoma – A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)
2025 年 5 月 1 日
ADC
OBI-992, a Novel TROP2 Antibody-Drug Conjugate, Exhibits Distinct Resistance Profiles Compared to other TROP2 Targeting ADCs
2025 年 5 月 1 日
ADC
OBI-902, a Novel TROP2-Targeted Antibody-Drug Conjugate via GlycOBI® Platform, Has Favorable Pharmacokinetics and Sustained Antitumor Activities in Challenging Solid Tumors
2025 年 5 月 1 日
Technology
Harnessing the GlycOBI® Enabling Technologies: Next-generation Site-Specific Glycan ADCs with Versatile DAR to Enhance Therapeutic Index
2025 年 5 月 1 日
Technology
ThiOBI® Platform, a Novel Hydrophilic Linker for Irreversible Cysteine-selective Biomolecular Conjugation, Demonstrated Potent and Durable Antitumor Activities in Various Animal Models
2025 年 3 月 14 日
ADC
Preclinical Evaluation of a Novel Antibody-Drug Conjugate OBI-992 for Cancer Therapy
2024 年 12 月 4 日
ADC